Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Virpax Pharmaceuticals
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
August 08, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Regains Compliance with Nasdaq Minimum Bid Price
July 24, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
July 10, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
May 29, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
April 30, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
November 17, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
October 31, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
October 02, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
September 18, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Updates on Litigation
September 05, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
July 13, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces CFO Transition
June 20, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Reports on Progress of Envelta™
April 05, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
March 28, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
February 13, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pursues OTC Medical Device Pathway for AnQlar™
July 05, 2022
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis
June 27, 2022
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021
September 02, 2021
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board
July 30, 2021
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax to Use Envelta™ IND Enabling Study Results for Two Additional Indications
June 21, 2021
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.